March 6, 2023 -

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

March 6th, 2023 Cancer, Cancer treatment in China, CAR T-Cell therapy

SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today tha.... Read More

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

March 6th, 2023 Cancer, Cancer treatment in China, Liver cancer

SHANGHAI, CHINA, February 28, 2023 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clini.... Read More

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

March 6th, 2023 Cancer, Cancer treatment in China, CAR T-Cell therapy, Drugs, Immunotherapy

SHANGHAI, CHINA, December 12, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical dat.... Read More

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

March 6th, 2023 Cancer, Cancer treatment in China, CAR T-Cell therapy, Immunotherapy

SHANGHAI, CHINA, November 9, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as of November 8, 2.... Read More

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

March 6th, 2023 Cancer, Cancer treatment in China, CAR T-Cell therapy, Immunotherapy

SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, a.... Read More

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

March 6th, 2023 Cancer, Cancer treatment in China, CAR T-Cell therapy, Lymphoma, Treatment, Treatment in China

SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medica.... Read More